不同剂量阿托伐他汀治疗急性冠脉综合征临床疗效对比分析

Effects and safety about different doses of atorvastatin treatment in patients with acute coronary syndrome

目的使用2种不同剂量阿托伐他汀治疗急性冠脉综合征(ACS),观察疗效及并发症情况。方法将100例ACS患者按随机分为两组,试验组给予阿托伐他汀40 mg/d,观察组10 mg/d,口服用药时间为1年。观察2组患者血脂变化情况、住院期间及存活出院者主要心血管事件及药物不良反应。结果 2组患者在治疗3、6及12个月的血清总胆固醇及低密度脂蛋白胆固醇浓度均比治疗前明显降低,差异有统计学意义(P<0.05);且试验组在各时间段的血清总胆固醇及低密度脂蛋白胆固醇等浓度均低于观察组,差异有统计学意义(P<0.05)。住院及后期随访中试验组心力衰竭、复发性心绞痛、心律失常发生率均较对照组明显降低,差异均有统计学意义(P<0.05)。2组均未见严重不良反应。结论应用较大剂量阿托伐他汀治疗ACS安全有效。

Objective To observe the effects and complications of two different doses of atorvastatin in patients with acute coronary syndrome （ACS）. Methods 100 patients with ACS were randomly divided into two groups, which were respectively treated with atorvastatin 10 mg or 40 mg a day for one year. The effects of the two doses of atorvastatin on lipid levelsincidence of cardiocerebral vascular events and survival during hospitalization and side effects were observed respectively. Results When compared with base levels, the serum concentrations of ow density lipoprotein -cholesterol （LDL -C ）and total cholesterol （TC） were significantly decreased （P 〈 0.05 ）, in both groups ＇after 3 months, 6 monthand 12 months. The level of LDL - C and TC were lower in all three observation periods in group with 40mg atorvastatin than that in 10mg atorvastatin. （ P 〈 0.05）. In 40 mg groups, incidence of cardiocerebral vascular events such as recurrent angina pectoris, heart failure, arrhythmia were lower than those of 10 mg group during hospitalization and 12 - month＇s follow - up period. There were no serious adverse events in two groups. Conclusion Larger dose atorvastatin treatment of patients with ACS is safe and effective.